Ainos Inc. Common Stock (AIMD)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for a business that can earn money without constant outside financing, and Ainos does not yet fit that description. It has a dual platform in AI olfaction and immune therapeutics, but the filed numbers are tiny. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $152 and net income was -$4.6 million, with diluted EPS of -$0.62. Fiscal Q1 2026, ended 2026-03-31, showed revenue of $161 and a net loss of $2.5 million. For full-year fiscal 2025, revenue was $124,157 and net income was -$14.8 million; fiscal 2024 revenue was $20,729 and net income was -$14.9 million. Those are not the marks of a durable enterprise, and I see no evidence in these figures of a moat that would protect pricing or margins. The balance sheet and cash flow are strained. Free cash flow for the trailing twelve months was -$4.4 million, a FairStock calculation, and FCF yield was -55.0% against the $8.0 million market cap. Debt-to-equity was 4.21, Altman Z-Score was -4.94, and Piotroski F-Score was 3/9. Return on equity was -196.30% and return on capital employed -39.57%, both FairStock calculations. At the 2026-10-13 close of $1.08, the P/E is -0.43 and P/B is 2.40, also FairStock calculations. The Lynch category is none because the company lost money in each of the last four years. Growth is a promise, not a record. Revenue in fiscal 2023 was $122,112 and in fiscal 2025 $124,157, so the top line has not compounded. With 41 employees and a $8.0 million market value, this is speculative. Graham would demand a margin of safety in earnings and assets; here I find neither. The price may be low in absolute dollars, but it is not cheap against the business’s current numbers.

In plain English: Ainos is a tiny technology company working on AI smell technology and immune treatments; it has only 41 employees and very little revenue. In the latest filed quarter, the quarter ended 2026-06-30, revenue was just $152 and the company lost $4.6 million, so the business looks very weak and unprofitable. At the $1.08 close on 2026-10-13, the stock price looks expensive relative to the company’s tiny sales and continuing losses, and the main question is whether it can survive and grow.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer